<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Protein-bound <z:chebi fb="5" ids="18154">polysaccharide</z:chebi> K (PSK) has been used as a chemoimmunotherapy agent for the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, PSK was reported to be able to decrease some adverse effects of FOLFOX therapy, including <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and peripheral neurotoxicity </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we report 2 patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>, who unexpectedly were able to receive many courses of PSK+mFOLFOX6 therapy for a prolonged period </plain></SENT>
<SENT sid="3" pm="."><plain>We speculate that FOLFOX therapy may achieve long-term <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> control with the aid of PSK without serious side effects for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> patients </plain></SENT>
</text></document>